Literature DB >> 23331679

Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis.

Andrea J Gonzales1, William R Humphrey, James E Messamore, Timothy J Fleck, Gregory J Fici, John A Shelly, Janet F Teel, Gary F Bammert, Steven A Dunham, Troy E Fuller, Robert B McCall.   

Abstract

BACKGROUND: Interleukin-31 (IL-31) is a member of the gp130/interleukin-6 cytokine family that is produced by cell types such as T helper 2 lymphocytes and cutaneous lymphocyte antigen positive skin homing T cells. When overexpressed in transgenic mice, IL-31 induces severe pruritus, alopecia and skin lesions. In humans, IL-31 serum levels correlate with the severity of atopic dermatitis in adults and children. HYPOTHESIS/
OBJECTIVE: To determine the role of IL-31 in canine pruritus and naturally occurring canine atopic dermatitis (AD). ANIMALS: Purpose-bred beagle dogs were used for laboratory studies. Serum samples were obtained from laboratory animals, nondiseased client-owned dogs and client-owned dogs diagnosed with naturally occurring AD.
METHODS: Purpose-bred beagle dogs were administered canine interleukin-31 (cIL-31) via several routes (intravenous, subcutaneous or intradermal), and pruritic behaviour was observed/quantified via video monitoring. Quantitative immunoassay techniques were employed to measure serum levels of cIL-31 in dogs.
RESULTS: Injection of cIL-31 into laboratory beagle dogs caused transient episodes of pruritic behaviour regardless of the route of administration. When evaluated over a 2 h period, dogs receiving cIL-31 exhibited a significant increase in pruritic behaviour compared with dogs that received placebo. In addition, cIL-31 levels were detectable in 57% of dogs with naturally occurring AD (≥ 13 pg/mL) but were below limits of quantification (<13 pg/mL) in normal, nondiseased laboratory or client-owned animals.
CONCLUSIONS: Canine IL-31 induced pruritic behaviours in dogs. Canine IL-31 was detected in the majority of dogs with naturally occurring AD, suggesting that this cytokine may play an important role in pruritic allergic skin conditions, such as atopic dermatitis, in this species.
© 2013 Pfizer Inc. Veterinary Dermatology © 2013 ESVD and ACVD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331679     DOI: 10.1111/j.1365-3164.2012.01098.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  23 in total

1.  Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression.

Authors:  Ramakrishna Edukulla; Brijendra Singh; Anil G Jegga; Vishwaraj Sontake; Stacey R Dillon; Satish K Madala
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

2.  Itch in dermatomyositis: the role of increased skin interleukin-31.

Authors:  H J Kim; M Zeidi; D Bonciani; S M Pena; J Tiao; S Sahu; V P Werth
Journal:  Br J Dermatol       Date:  2018-06-21       Impact factor: 9.302

3.  Current Knowledge on Canine Atopic Dermatitis: Pathogenesis and Treatment.

Authors:  Catherine A Outerbridge; Tyler J M Jordan
Journal:  Adv Small Anim Care       Date:  2021-09-29

Review 4.  Interleukin-31: a novel diagnostic marker of allergic diseases.

Authors:  Anja Rabenhorst; Karin Hartmann
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

5.  Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.

Authors:  K Kasutani; E Fujii; S Ohyama; H Adachi; M Hasegawa; H Kitamura; N Yamashita
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?

Authors:  Tong Liu; Ru-Rong Ji
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

7.  The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus.

Authors:  Hua-Tuo Huang; Jian-Ming Chen; Jing Guo; Yan Lan; Ye-Sheng Wei
Journal:  Rheumatol Int       Date:  2016-01-14       Impact factor: 2.631

Review 8.  Common and discrete mechanisms underlying chronic pain and itch: peripheral and central sensitization.

Authors:  Chengjin Li; Hee Jin Kim; Seung Keun Back; Heung Sik Na
Journal:  Pflugers Arch       Date:  2021-07-10       Impact factor: 3.657

9.  Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.

Authors:  Timothy J Fleck; Lori R Norris; Sean Mahabir; Rodney R Walters; Olivier Martinon; Steven A Dunham; Andrea J Gonzales
Journal:  Vet Dermatol       Date:  2021-04-08       Impact factor: 1.867

10.  Expression of barrier proteins in the skin lesions and inflammatory cytokines in peripheral blood mononuclear cells of atopic dogs.

Authors:  Sarita Kanwal; Shanker K Singh; Sandeep P Soman; Soumen Choudhury; Priyambada Kumari; Pradeep K Ram; Satish K Garg
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.